Angiogenic therapy offers promise for reducing claudication

June 13, 2002

Results of a study in this week's issue of THE LANCET highlight the potential for angiogenic therapy--the use of genes, proteins, and other molecular agents to stimulate growth of new blood vessels--to improve peripheral blood flow for people with intermittent claudication caused by atherosclerosis.

Peripheral artery disease affects up to 15% of adults over the age of 55 years; a third are estimated to have typical intermittent claudication (cramp-like pain in the legs during exercise caused by restricted blood flow, often a result of obstructive atherosclerosis). The protein recombinant fibroblast growth factor-2 (rFGF-2) can cause growth and proliferation of blood vessels from existing vascular structures (angiogenesis). Robert Lederman, formerly of the University of Michigan, Brian Annex from Duke University Medical Centre, USA, and colleagues investigated whether one or two doses of intra-arterial rFGF-2 improves exercise capacity in patients with moderate-to-severe intermittent claudication (the TRAFFIC study).

190 patients with intermittent claudication of the calf muscle caused by atherosclerosis were randomly assigned bilateral intra-arterial infusions of placebo on days 1 and 30 (the control group); rFGF-2 (30 mg/kg) on day 1 and placebo on day 30 (single-dose group); or rFGF-2 (30 mg/kg) on days 1 and 30 (double-dose group).

Data were available for 174 patients. Peak walking time at 90 days was increased by 0.6 minutes with placebo, by 1.77 minutes with single-dose rFGF-2, and by 1.54 minutes with double-dose rFGF-2.

Robert Lederman comments: "Intra-arterial rFGF-2 resulted in a significant increase in peak walking time at 90 days; repeat infusion at 30 days was no better than one infusion. The findings of TRAFFIC provide evidence of clinical therapeutic angiogenesis by intra-arterial infusion of an angiogenic protein."

In an accompanying Commentary, Richard Donnelly from the University of Nottingham, UK, concludes: "...the TRAFFIC study gives cautious optimism that experimental biotechnology can deliver a safe and effective therapy which, via new vessel formation, improves symptoms and lower-limb outcome in patients with peripheral arterial disease. Therapeutic angiogenesis in the lower limb would be especially attractive when revascularisation is not feasible or has failed, or when the risks of critical ischaemia and distal amputation are high."
-end-
Contact: Dr Robert J Lederman MD, National Heart Lung and Blood Institute, National Institutes of Health, 10 Center Drive, Building 10, Room 2c713, Bethesda, MD 20892-1538, USA; T) +1 301 402 6769; F) +1 301 451 5451; E) lederman@nih.gov

Dr Brian H Annex, MD, Duke University Medical Center, 508 Foulton St. Box 111A, Durham, NC 27705, USA; T) +1 919 286-0411 extension 7258; F) +1 919 286-6861; E) annex001@mc.duke.edu.

Professor Richard Donnelly, School of Medical and Surgical Sciences, University of Nottingham, and Southern Derbyshire Acute Hospitals NHS Trust, Derby DE1 2QY, UK; E) Richard.donnelly@nottingham.ac.uk

Lancet

Related Atherosclerosis Articles from Brightsurf:

How hormone therapy slows progression of atherosclerosis
As one of the most common treatments for effectively managing menopause symptoms, hormone therapy (HT) is also known to provide multiple health benefits, including slowing the progression of atherosclerosis.

T cells can shift from helping to harming in atherosclerosis
At La Jolla Institute for Immunology (LJI) researchers are dedicated to finding a way to stop plaques from forming in the first place.

New nanoparticle drug combination for atherosclerosis
Physicochemical cargo-switching nanoparticles (CSNP) designed by KAIST can help significantly reduce cholesterol and macrophage foam cells in arteries, which are the two main triggers for atherosclerotic plaque and inflammation.

Atherosclerosis -- How a microRNA protects vascular integrity
Ludwig-Maximilian-Universitaet (LMU) in Munich researchers have discovered a hitherto unknown molecular function of a specific microRNA that preserves integrity of the endothelium and reduces the risk of atherosclerosis.

Atherosclerosis progresses rapidly in healthy people from the age of 40
A CNIC study published in JACC demonstrates that atheroma plaques extend rapidly in the arteries of asymptomatic individuals aged between 40 and 50 years participating in the PESA-CNIC-Santander study.

Scaling up a nanoimmunotherapy for atherosclerosis through preclinical testing
By integrating translational imaging techniques with improvements to production methods, Tina Binderup and colleagues have scaled up a promising nanoimmunotherapy for atherosclerosis in mice, rabbits and pigs -- surmounting a major obstacle in nanomedicine.

Bladder drug linked to atherosclerosis in mice
A drug used in the treatment of overactive bladder can accelerate atheroclerosis in mice, researchers at Karolinska Institutet in Sweden report in a study published in the Proceedings of the National Academy of Sciences (PNAS).

A new therapeutic target for blocking early atherosclerosis in progeria
Researchers at the Centro Nacional de Investigaciones Cardiovasculares and the Universidad de Oviedo have discovered a new molecular mechanism involved in the premature development of atherosclerosis in mice with Hutchinson-Gilford progeria syndrome.

Protective mechanism against atherosclerosis discovered
Immune cells promoting inflammation play a crucial role in the development of atherosclerosis.

Atherosclerosis: Stopped on time
For the first time, LMU researchers are pointing out the influence of the internal clock on atherosclerosis.

Read More: Atherosclerosis News and Atherosclerosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.